Rhythm Pharmaceuticals (Rhythm Pharmaceuticals) Change In Working Capital : $-0.13 Mil (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Rhythm Pharmaceuticals Change In Working Capital?

Rhythm Pharmaceuticals's change in working capital for the quarter that ended in Mar. 2024 was $-2.19 Mil.

Rhythm Pharmaceuticals's change in working capital for the fiscal year that ended in Dec. 2023 was $4.81 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Rhythm Pharmaceuticals Change In Working Capital Historical Data

The historical data trend for Rhythm Pharmaceuticals's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhythm Pharmaceuticals Change In Working Capital Chart

Rhythm Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

5.07

-5.90

1.90

-17.41

4.81

Rhythm Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Working Capital	Get a 7-Day Free Trial															2.75	-9.68	2.83	8.91	-2.19

Rhythm Pharmaceuticals Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.13 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Rhythm Pharmaceuticals Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Rhythm Pharmaceuticals's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Rhythm Pharmaceuticals (Rhythm Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rhythm Pharmaceuticals Inc (NAS:RYTM) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

RYTM:Mexico 1RV:Germany

Address

222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116

Website

http://www.rhythmtx.com

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies.

Executives

Joseph Shulman	officer: Chief Technical Officer	C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Hunter C Smith	officer: CFO and Treasurer	C/O GENESEE & WYOMING INC., 20 WEST AVENUE, DARIEN CT 06820
Jennifer Chien	officer: EVP, Head of North America	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Christopher Paul German	officer: Corporate Controller & CAO	C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Pamela J. Cramer	officer: Chief Human Resources Officer	C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
William T. Roberts	officer: Chief Accounting Officer	C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Yann Mazabraud	officer: EVP, Head of International	C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FLOOR 14, NEW HAVEN CT 06510
Linda Shapiro Manning	officer: Chief Medical Officer	C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
David P Meeker	director	C/O PENWEST PHARMACEUTICALS CO, 39 OLD RIDGEBURY ROAD SUITE 11, DANBURY CT 06810
Todd Foley	director, 10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Lynn A. Tetrault	director	12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Camille L Bedrosian	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Nithya Desikan	officer: Chief Commercial Officer	82 BAY STATE ROAD, BELMONT MA 02478
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116